Stay updated on Avutometinib and Defactinib in Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page.

Latest updates to the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to reflect a new phase II clinical trial for thyroid cancer treatments, specifically detailing the evaluation of avutometinib and defactinib for radioiodine-refractory patients. Key collaborators and the principal investigator have also been specified.SummaryDifference51%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 13, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check80 days agoChange DetectedThe webpage has updated its date references, removing older dates from January 2025 and adding new dates in February 2025.SummaryDifference0.4%
Stay in the know with updates to Avutometinib and Defactinib in Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avutometinib and Defactinib in Thyroid Cancer Clinical Trial page.